Sarabjit Kour Nangra

DRL Q2 in line with view, coming qtrs may not be great: experts

The earning numbers a mostly in line with estimates and Angel Broking keeps a neutral rating on the stock, says Sarabjit Kour Nangra of Angel Broking.

Crack The Code: Decoding pharma sector

CNBC-TV18's Sumaira Abidi spoke with Sarabjit Kour Nangra, VP-Research at Angel Broking and Surajit Pal, AVP-Analyst Pharma at Prabhudas Lilladhar about healthcare sector at length.

No disturbing trend in Dr Reddy's numbers except topline: Expert

Shetty says that she has her doubts on a possible revival of revenues saying that the eight drugs bought from Teva for the US market, will take till 2019 to affect Dr Reddy's revenues.

Energy vertical pickup critical for Wipro to regain growth: Pros

Ravi Menon of Elara Capital, in an interview to CNBC-TV18, said there is some uptick in capex in the energy space which might provide some fillip to Wipro's IT business in the coming years. However, for now this vertical will prove to be a drag.

Wipro Q4 in line; Q1FY17 guidance disappointing: Analysts

Sarabjit Kour Nangra of Angel Broking said that she was disappointed with the guidance number as Wipro has made a few acquisitions and sees a sharp down trend in its stock on Thursday.

TCS Q4 margins disappoint but FY17 outlook good: Analysts

Rahul Jain of Systematix Shares and Stocks pointed out that contribution from the digital segment has seen good improvement, adding, he expects this segment to provide reasonable incremental revenue going forward.

USFDA scans Cipla's Indore plant over norms violations

As per USFDA guidelines, Form 483 notifies a company's management of objectionable conditions following inspection of manufacturing plant or units.

Wipro up 2%, aims to buy strategic design firm in Denmark

â€œWipro Digital, the digital business unit of Wipro, announced its intention to acquire Designit, an award winning and global strategic design firm specializing in designing transformative product-service experiences," said the company in its filing to the exchange.

Tech Mahindra gains 2% on tie up with BPM software vendor

"PNMsoft, a global provider of intelligent BPM software solutions, has collaborated with Indian IT exporter Tech Mahindra to offer superior customer experiences," said the company in its filing to the exchange.

Infosys gains on hopes of meeting NASSCOM FY16 guidance

Shares of Infosys rallied 1.7 percent intraday Thursday on reports that the country's second largest IT services exporter may meet NASSCOM's FY16 guidance.

Ranbaxy effect playing on Sun Pharma's margins: Pros

Sarabjit Kour Nangra, VP- Research, Angel Broking, believes it to be the Ranbaxy effect. However, she says 14.5 percent is very low, because after consolidation she was looking at closer to 30 percent.

Infosys dives 6% post poor Q4 results; TCS gains 2%

Infosys posted 0.4 percent decline in constant currency revenue growth at USD 2,208 million during the quarter, which was far lower than its peers TCS (1.6 percent growth), HCL Technologies (2.7 percent) and Wipro (1.2 percent).

IPCA Labs tanks 9%, gets USFDA import alert for Ratlam unit

Investors offloaded a huge chunk of shares of Ipca Laboratories on Friday. The stock fell nearly 9 percent intraday. The pharmaceutical firm received import alert from US Food and Drug Administration for its Ratlam unit due to violations of standard production practices.

Halol contributes 35-40% to Sun's US sales: Angel Broking

Nangra believes that most pharma stocks are trading at fair valuations post the recent run-up in the market. She likes Dr Reddys and IPCA Labs in the space.

Ranbaxy shares surge nearly 6% as Q4 net loss narrows

Ranbaxy Laboratories's fourth-quarter net loss narrowed to Rs 158.94 crore, mainly on account of higher sales of its Absorica acne drug.

GSK Pharma a long term bet: Experts

But Daljit Singh Kohli, IndiaNivesh Securities advises investors to tender in the offer and get out.

Mohali import alert huge setback for Ranbaxy: Angel Broking

This import alert is a huge negative for Ranbaxy because this is relatively a new facility, which the company was betting on for growth going forward, says Sarabjit Kour Nangra of Angel Broking.

Lupin hit by drug pricing; biz did well globally: Angel

Sarabjit Kour Nangra of Angel Broking believes that India‘s drug pricing policy impacted Lupin‘s earnings for June quarter. The pharmaceutical major posted a 43 percent net profit year-on-year (YoY), but revenues rose lower-than-expected 10 percent YoY.